Clinical Trial Update: Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial update on APP13007 for ocular inflammation and pain after cataract surgery; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Inflammation
• Pain After Cataract Surgery

Drugs mentioned

• APP13007

Snippet

Sponsor: Formosa Pharmaceuticals, Inc. | Conditions: Ocular Inflammation and Pain | Phase 3 | Status: COMPLETED | Results posted: 2023-07-05